Australia's Starpharma hits 1-month high on prostate cancer drug results

Starpharma Holdings

18/10/2023 01:46

** Shares of Australia-based global biopharmaceutical
company Starpharma Holdings  SPL.AX  rise as much as 37% to
A$0.185, their highest level since Sept 13
    ** Stock posts its biggest intraday pct gain since Sept 18
    ** Co says DEP cabazitaxel phase 2 clinical trial met its
objectives, with endpoints demonstrating positive anti-tumour
efficacy in multiple cancers 
    ** DEP cabazitaxel is a nano-version of leading prostate
cancer drug cabazitaxel
    ** Trial results confirmed favourable safety and
tolerability profile of DEP cabazitaxel 
    ** Nearly 5.98 mln shares change hands, vs 30-day average
volume of 1.64 mln shares
    ** SPL biggest percentage gainer in the ASX All Ordinaries
index  .AORD 
    ** Starpharma stock down ~75.5% YTD, as of last close
    

 (Reporting by Roshan Thomas in Bengaluru)
 ((Roshan.Thomas@thomsonreuters.com;))